Pharma’s strong pipelines, reduced policy risks, and demand growth drive renewed investor interest. This Pharmaceutical ETF offers targeted access to top innovators like Eli Lilly and Merck.
Pharmaceuticals sit at the intersection of innovation and defensiveness, where pipelines turn science into cash flows and global demand adds resiliency. With policy clarity improving and investors rotating back to quality, the setup for large-cap pharma looks attractive.
This post appeared first on ETF Trends.